Date: 2016-11-17
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Imara (USA - MA)
Product: IMR-687 - 6-[(3S,4S-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imadazo[1,5-a]pyrazin-8-one
Action
mechanism: phosphodiesterase 9 inhibitor. IMR-687 is a highly potent, selective inhibitor of phosphodiesterase-9 (PDE9i) in blood cells. IMR-687 was specifically designed to address the underlying pathology of sickle cell disease. Pre-clinical data demonstrate IMR-687 reduces both the sickling of red blood cells and blood vessel occlusion that cause debilitating pain, organ damage, and early mortality in affected patients.
Disease: sickle cell disease
Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases
Country: USA
Trial
details: The purpose of this Phase 1a, first in human, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, PK and PD profile of the orally administered IMR-687 in healthy adult subjects. (NCT02998450)
Latest
news: * On November 17, 2016, Imara announced the first healthy volunteer has been dosed in a phase 1 clinical study evaluating the safety and tolerability of its lead product candidate, IMR-687.
